Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University. https://themarketherald.com.au/immuron-asximc-takes-steps-towards-fda-approval-for-stomach-bug-treatment-2020-10-12/

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.